Bassil Dahiyat has been Xencor’s president and chief executive officer since the Company’s incorporation in August 1997. He is the co-founder of Xencor and co-inventor of Xencor’s breakthrough XmAb^® technology. He has led the Company in creating a diverse clinical-stage portfolio of engineered antibodies and cytokines for the treatment of life-threatening and debilitating diseases, and has established alliances with leading biopharmaceutical companies that have resulted in three marketed drugs. Dr. Dahiyat has co-authored numerous scientific papers in the fields of protein design and drug delivery, is an inventor of over 30 U.S. and numerous foreign patents and has received scientific awards from the American Chemical Society, the Controlled Release Society, the Protein Society and Caltech. Dr. Dahiyat also serves as a member of the board of directors of Kodiak Sciences and Terray Therapeutics. He holds a Ph.D. in Chemistry from Caltech and B.S. and M.S.E. degrees in Biomedical Engineering from the Johns Hopkins University.

Dr. Desjarlais oversees all aspects of discovery and research at the company, including technology development, protein and antibody engineering and generation of drug candidates, and has served as chief scientific officer since 2014. Before joining Xencor in 2001, Dr. Desjarlais was an Assistant Professor of Chemistry at Penn State University, where he developed protein engineering methods. He then conducted postdoctoral research at the University of California, Berkeley. Dr. Desjarlais received a B.S. in physics from the University of Massachusetts and a Ph.D. in biophysics from Johns Hopkins University. He completed a post-doctoral fellowship at the University of California, Berkeley.

Mr. Leone guides Xencor’s strategy to achieve corporate goals by supporting the Company’s R&D and clinical leadership, overseeing assessment and prioritization of current and future XmAb® drug programs and overseeing business development and investor relations activities. Mr. Leone most recently was leading equity research analyst, serving as a managing director and senior biotechnology analyst at Raymond James. Mr. Leone’s focus areas in equity research included oncology, immunology, cardiology and ophthalmology. His coverage spanned securities across a wide range of market capitalization, from biotechnology companies advancing a diverse set of drug candidates to commercializing novel medicines. Before Raymond James, Mr. Leone held analyst roles with increasing seniority at BTIG and Macquarie Securities Group. He began his career in portfolio management as a health care and quantitative research analyst at AllianceBernstein. Mr. Leone received his B.S. in business from the State University of New York at Albany. He holds the Chartered Financial Analyst® designation from the CFA® Institute.

CFA® and Chartered Financial Analyst® are registered trademarks of CFA Institute.

Mr. Cornelissen brings more than 20 years of experience in corporate financial planning, analysis and transactions to Xencor, where he has primary responsibility for financial reporting, budgeting, cash-flow management, investments, information technology and facilities. Before Xencor, Mr. Cornelissen was vice president, corporate finance at Seagen Inc., where he built and scaled the corporate finance organization to support tremendous revenue growth and dealmaking activity, including the company’s $43 billion acquisition by Pfizer in 2023. Before Seagen, while at the Bill & Melinda Gates Foundation, he served as vice president, finance for the END Fund and as finance lead for malaria and neglected tropical disease initiatives. Earlier in his career, Mr. Cornelissen led multiple finance teams at DSM Nutritional Products, a former division of Roche. He began his career in life sciences and health within global financial planning and analysis at Novartis. Mr. Cornelissen received his M.Sc. in Business Administration from the Rotterdam School of Management at Erasmus University.

Ms. Eckert joined Xencor as vice president, general counsel and corporate secretary in September 2019. Previously, she served as vice president, corporate legal at Synthetic Genomics. In that role, she negotiated licensing and financial transactions and supported other corporate legal matters. Before Synthetic Genomics, Ms. Eckert served as associate general counsel at Sequenom and as senior director, legal affairs at Prometheus Laboratories. At Prometheus, she structured transactions, managed substantial patent litigation and supported the growth of the company’s commercial organization. Earlier in her career, she was an associate at Jones Day and at Pillsbury Winthrop Shaw Pittman LLP. Ms. Eckert earned a B.A. in political science from the University of California, Los Angeles, and a J.D. from the University of California, College of the Law, San Francisco.

Dr. Humerickhouse is responsible for leading Xencor’s clinical development and medical affairs strategy and execution in oncology. Before joining Xencor in April 2024, he served as vice president, hematology at Bristol Myers Squibb. In this role, he was responsible for development strategy for multiple late-stage assets, setting overall disease strategy, guiding project prioritization and informing early clinical development and business decisions. Prior to BMS, he spent 20 years in roles of increasing responsibility at Abbvie/Abbott Laboratories leading teams for VENCLEXTA® and other programs, including Bcl-2 inhibitors, VEGF TKI (linifanib) and anti-EGFR antibodies. Dr. Humerickhouse received his M.D. and Ph.D. at Indiana University School of Medicine and completed both his internal medicine training and hematology/oncology fellowship at the University of Chicago Hospitals.

Dr. Hung is responsible for leading Xencor’s clinical development strategy and execution in autoimmune disease. Prior to joining Xencor in April 2024, he held roles of increasing responsibility over a decade at Pfizer within precision medicine, inflammation and immunology. Most recently, he served as the gastroenterology therapeutic area lead where he led clinical development for programs in ulcerative colitis and Crohn’s disease for an anti-TL1A Mab. Prior to Pfizer, he held faculty roles at Tufts University, including in the Division of Gastroenterology in the Department of Medicine. Dr. Hung received his M.D. and Ph.D. from The John Hopkins University School of Medicine and completed his internal medicine training at the Hospital of the University of Pennsylvania, followed by gastroenterology fellowship at Massachusetts General Hospital.

Mr. Kowack oversees all aspects of the program leadership and strategic alliances group in support of Xencor’s internal and external portfolios. Previously, he served as vice president of program leadership and precision medicine at Ignyta, where he led early-stage development programs while spearheading Ignyta’s contributions to the Cancer Moonshot initiative. Mr. Kowack has extensive experience leading oncology-focused drug development teams at Pfizer, where he served as asset team leader for 19 different programs, including Ibrance^® (palbociclib) from Ph 1b to approval. Mr. Kowack served in the United States Coast Guard in several roles of increasing responsibility, including Commanding Officer of a cutter, before retiring as a Commander in the USCGR. He earned an M.S. in biochemistry from Dartmouth College and an MBA from Marist.

Mr. Rosemark brings to Xencor over 25 years of biopharmaceutical industry experience, leading regulatory affairs and quality assurance organizations, developing and registering products with regulatory authorities and supporting them throughout their lifecycles. Before joining Xencor, he most recently served as vice president, regulatory affairs at Beigene (USA), where he developed and evaluated regulatory approval strategies for multiple development projects and combinations thereof and held responsibility for 14 INDs. Before Beigene, Mr. Rosemark was vice president, regulatory affairs and quality assurance at CymaBay Therapeutics, where he led the regulatory strategies for several mid-to-late stage programs, several of which with preferential designations with health authorities. From 2003 to 2014, he was vice president, regulatory affairs and quality assurance at Exelixis, where he led to the regulatory team on the Cometriq^® program, taking it from discovery through approvals in the U.S. and EU. Earlier in his career he held roles of increasing responsibility in regulatory affairs at Solvay Pharmaceuticals, Ciba Vision and Bausch & Lomb Pharmaceuticals. Mr. Rosemark received a B.S. in chemistry from Cleveland State University.

Ms. Sandoz brings 25 years of wide-ranging healthcare experience to Xencor, where she is responsible for leading Xencor’s overall human resources strategy. Ms. Sandoz previously served as Vice President, Human Resources at Surgical Care Affiliates, an OptumCare company, where she led teams in talent acquisition, compensation, and learning & organizational development. Before Surgical Care Affiliates, she held progressively more senior roles in human resources at Amgen, following a role as a program manager on their first oncology BLA submission, for Vectibix^® (panitumumab). Earlier in her career, she worked in management consulting at Deloitte and in clinical research at Parke-Davis (now Pfizer). Ms. Sandoz received a B.S. in nursing from the University of Pennsylvania and an M.S. in nursing from the University of Michigan.